The sharp decline in ZyVersa Therapeutics' share price is a direct result of the public offering announcement. Public offerings often lead to dilution of shares, causing a negative reaction in the market. The offering price being set below the current trading price further exacerbates the issue, as it indicates a potential undervaluation of the shares or a need for the company to raise capital quickly, both of which can be perceived negatively by investors.